Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
All content curated by
Published in Oncology

Journal Scan / Research · August 04, 2024

Clinicopathological and Molecular Changes Induced by Neoadjuvant Chemotherapy and Endocrine Therapy in HR-Positive/HER2-Low and HR-Positive/HER2-0 Breast Cancer

ESMO Open

 

Additional Info

ESMO Open
Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancer
ESMO Open 2024 Jun 28;9(7)103619, F Schettini, S Nucera, F Brasó-Maristany, I De Santo, T Pascual, M Bergamino, P Galván, B Conte, E Seguí, I García Fructuoso, R Gómez Bravo, P Rivera, AB Rodríguez, O Martínez-Sáez, S Ganau, E Sanfeliu, B González-Farre, MJ Vidal Losada, B Adamo, I Cebrecos, E Mension, G Oses, P Jares, S Vidal-Sicart, M Mollà, M Muñoz, A Prat

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading